In this episode of BJD Talks, Sam and Meera discuss the article ‘Rademikibart monotherapy for moderate-to-severe atopic dermatitis in a 1-year, randomized phase II trial (SEASIDE CHINA): initial 2-week dosing, followed by 2-week or 4-week dosing’ by Zhang et al. The full article can be accessed at https://doi.org/10.1093/bjd/ljaf346 

*This podcast was generated by an AI tool created by 67Bricks for the British Association of Dermatologists*